Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

SCTX

Scribe Therapeutics Inc

22.22

Jul 24 • 2:14 PM ET +7.22 (48.13%)

Healthcare Biotechnology USA NASD

Today, 12:01 PMScribe Therapeutics surges 60% on strong-demand Nasdaq IPO debut

Scroll to Statements

Index	-
Market Cap	-
Enterprise Value	-
Income	-
Sales	-
Book/sh	-9.81
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	98
IPO	Jul 24, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.66
Current Ratio	0.66
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / No

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	-
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	0.00%
SMA50	0.00%
SMA200	0.00%
Trades

Shs Outstand	16.18M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	- -
52W Low	- -
Volatility	- -
ATR (14)	3.49
RSI (14)	-
Beta	-
Rel Volume	-
Avg Volume	-
Volume	612,642

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	15.00
Price	22.22
Change	48.13%

Scribe Therapeutics, Inc. is a clinical-stage biotechnology company. It is engaged in the development of in vivo therapies. It develops custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company was founded in June 2017 by Jennifer A. Doudna, Benjamin L. Oakes, David F. Savage, and Brett T. Staahl and is headquartered in Alameda, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SCTX

Scribe Therapeutics Inc

Upgrade your Finviz experience